I have been in clinical practice as a transplant hepatologist at the University of Chicago Medicine since 2000, and have been the Medical Director of the Adult Liver Transplant Program since 2006. My large clinical practice consists of both general hepatology as well as transplant hepatology patients, but patients with cirrhosis and its various complications as well as liver transplant recipients are the patients that I find the most rewarding patients to care for.
I have served on American Society of Transplantation (AST) Women Health Community of Practice (WHCOP) Excecutive Board and currently am serving on the AST Liver and Intestinal Community of Practice (LICOP) Executive Board. I consider AST as my “transplant home” – a place where I can network with my transplant colleagues, become involved in transplant-related educational initiatives, and participate in discussions focused on public policies related to transplantation. It is also a home where I can seek advice from supportive colleagues on difficult questions that may arise during my daily interactions with liver transplant candidates and recipients.
I have personally witnessed the evolution of the medical care for liver transplant recipients over the past two decades that has led to better long-term graft and patient outcomes. Management of recurrent hepatitis C was my research interest, and fortunately, the burden of recurrent hepatitis C in liver transplant recipients is easing, and there is no question that the expected victory over this disease will translate to even longer survival and better lives in the this population. Improving liver transplant patient outcomes, both in the pre-transplant and post-transplant phases, is now taking the center stage of my research and clinical work, and I consider a personalized approach and nimble innovations to be basic elements in the daily management of these patients.